{
    "pmcid": "10886287",
    "qa_pairs": {
        "What future direction does the paper suggest to enhance DL-based antibody design?": [
            "Incorporating evolutionary conserved sequence information",
            "Focusing solely on computational methods",
            "Eliminating the use of experimental data",
            "Reducing collaboration between research groups"
        ],
        "What is one of the challenges mentioned in the paper regarding the use of deep learning models for SARS-CoV-2-specific antibody design?": [
            "Limited availability of specific datasets",
            "High computational cost of simulations",
            "Lack of interest from the scientific community",
            "Incompatibility with existing laboratory techniques"
        ],
        "What is the primary target for antibody and nanobody design discussed in the paper?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What role do experimental datasets play in the development of DL models for identifying neutralizing antibodies against SARS-CoV-2?": [
            "They are used to train DL models",
            "They are used to validate DL models",
            "They are used to replace DL models",
            "They are used to discard non-neutralizing antibodies"
        ],
        "Which computational techniques are highlighted for optimizing nanobody sequences against SARS-CoV-2?": [
            "Attention-based networks and generative models",
            "Support vector machines and decision trees",
            "K-means clustering and principal component analysis",
            "Linear regression and logistic regression"
        ]
    }
}